Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 03/04/20 at 12:20pm

COVID-19 coronavirus treatments dominate the news as the world looks for a vaccine. Johnson & Johnson announced that it has selected a candidate for a COVID-19 vaccine from potential constructs it has been investigating since January, and is targeting a Phase 1 study for September, while British American Tobacco has said it is developing a COVID-19 vaccine from tobacco plants.

In terms of potential treatments to alleviate the systems of the virus, the FDA have announced they will allow doctors to use convalescent plasma, collected from people who recovered from COVID-19, to treat those who are in critical condition from the virus. While EUSA Pharma has unveiled promising preliminary findings from an interim analysis of siltuximab in the treatment of serious respiratory complications arising from COVID-19, the leading cause of morbidity and mortality in patients affected by the novel coronavirus.

10. Johnson & Johnson selects lead COVID-19 vaccine candidate and targets September Phase I study

Johnson & Johnson announced that it has selected a candidate for a COVID-19 vaccine from potential constructs it has been investigating since January, and is targeting a Phase 1 study for September.

9. FDA approves BMS' Zeposia in relapsing multiple sclerosis, but COVID-19 will delay its market entry

Bristol-Myers Squibb has secured approval with the FDA for Zeposia (ozanimod) 0.92mg in relapsing forms of multiple sclerosis (RMS), but confirmed the drug wouldn’t be racing to market, as is usually the case.

8. British American Tobacco creating coronavirus vaccine

British American Tobacco has said it is developing a COVID-19 vaccine from tobacco plants.

7. People or profit: What is the best system to regulate drug prices?

Conor Kavanagh investigates the role state healthcare institutions play in negotiating drug prices, and what steps can be taken for a more mutually beneficial relationship to exist between pharmaceutical companies and governments when it comes to the pricing of drug products.

6. EMA gives market authorisation application to epilepsy treatment from Arvelle Therapeutics

The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for a cenobamate adjunctive treatment of focal-onset seizures in adults with epilepsy.

5. FDA will allow doctors to use convalescent plasma to treat critical COVID-19 patients

The FDA have announced they will allow doctors to use convalescent plasma, collected from people who recovered from COVID-19, to treat those who are in critical condition from the virus.

4. EUSA Pharma's COVID-19 drug improves or stabilises respiratory condition in 76% of patients

EUSA Pharma has unveiled promising preliminary findings from an interim analysis of siltuximab in the treatment of serious respiratory complications arising from COVID-19, the leading cause of morbidity and mortality in patients affected by the novel coronavirus.

3. COVID-19 may significantly hurt the drug supply chains of the biggest pharmaceutical companies

The increasing spread of the COVID-19 coronavirus pandemic threatens the drug supply lines of the biggest pharmaceutical companies, including AstraZeneca, Novartis and Roache.

2. WHO launches "historic" multinational study to investigate most promising COVID-19 therapies

The World Health Organization continues to push forward in the global fight against the novel coronavirus, and has announced the enrolment of the first patients in a set of “historic” multinational clinical trials to investigate four of the most promising therapies against the pathogen.

1. Hydroxychloroquine given to 1,100 patients with COVID-19 in New York

The malaria drug hydroxychloroquine is being administered to 1,100 patients in New York, which is fast becoming the new epicenter of the coronavirus pandemic.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches